Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 7:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 234 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Staphylococcus Aureus Clear all
Terminated Phase 2 Interventional Results available

Prevention of S. Aureus Pneumonia Study in Mechanically Ventilated Subjects Who Are Heavily Colonized With S. Aureus.

NCT02940626
View directory record Official record
Conditions
Pneumonia, Ventilator-associated, Pneumonia, Staphylococcal
Interventions
ASN100, Placebo
Drug
Lead sponsor
Arsanis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
17
States / cities
Phoenix, Arizona • Sacramento, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 20, 2026, 7:04 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus

NCT01645735
View directory record Official record
Conditions
Infections
Interventions
Ceftaroline fosamil, Ceftriaxone plus vancomycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Phoenix, Arizona • Sylmar, California • DeLand, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Oct 20, 2026, 7:04 PM EDT
Completed No phase listed Observational

Analysis of CA-MRSA Transmission: An ED Population Sampling Strategy

NCT02363166
View directory record Official record
Conditions
Methicillin-Resistant Staphylococcus Aureus
Interventions
Acute Abscess Group
Other
Lead sponsor
University of Florida
Other
Eligibility
1 Month and older
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 20, 2026, 7:04 PM EDT
Completed Phase 3 Interventional Results available

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

NCT02814916
View directory record Official record
Conditions
Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
Interventions
Dalbavancin, Vancomycin, Oxacillin, Flucloxacillin, Cefadroxil, Clindamycin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
0 Years to 17 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
15
States / cities
Mobile, Alabama • Phoenix, Arizona • La Palma, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 20, 2026, 7:04 PM EDT
Withdrawn Phase 1 Interventional

Pharmacokinetics of Vancomycin for Inhalation in Cystic Fibrosis

NCT01509339
View directory record Official record
Conditions
Cystic Fibrosis, Methicillin-resistant Staphylococcus Aureus
Interventions
Vancomycin
Drug
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Oct 20, 2026, 7:04 PM EDT
Completed No phase listed Observational

Detecting Infections Rapidly and Easily for Bacteremia Trial (DIREBT)

NCT01919762
View directory record Official record
Conditions
Bacteremia
Interventions
Not listed
Lead sponsor
T2 Biosystems
Industry
Eligibility
18 Years to 95 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 20, 2026, 7:04 PM EDT
Completed Phase 1 Interventional

Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics

NCT03162250
View directory record Official record
Conditions
Bacteremia
Interventions
DSTA4637S, Placebo, SOC
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Torrance, California • Detroit, Michigan • Royal Oak, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 20, 2026, 7:04 PM EDT
Completed Phase 4 Interventional

Animal-Assisted Visitation Program Chlorhexidine Trial

NCT04171817
View directory record Official record
Conditions
Methicillin-resistant Staphylococcus Aureus, Clostridium Difficile, Pseudomonas Aeruginosa
Interventions
Chlorhexidine
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
3 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Baltimore, Maryland • St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 7:04 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Efficacy Study of Altabax to Clear Methicillin-resistant Staphylococcus Aureus (MRSA) Nasal Colonization

NCT00856089
View directory record Official record
Conditions
Methicillin-resistant Staphylococcus Aureus
Interventions
Retapamulin
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 20, 2026, 7:04 PM EDT
Completed Phase 3 Interventional

Vancomycin Or Trimethoprim/Sulfamethoxazole for Methicillin-resistant Staphylococcus Aureus Osteomyelitis

NCT00324922
View directory record Official record
Conditions
Osteomyelitis, Methicillin-resistant Staphylococcus Aureus
Interventions
trimethoprim-sulfamethoxazole, vancomycin
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Oct 20, 2026, 7:04 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Bacterial Contamination Rates Between Isolation and Non-isolation Rooms

NCT01671358
View directory record Official record
Conditions
Methicillin-Resistant Staphylococcus Aureus
Interventions
Not listed
Lead sponsor
West Virginia University
Other
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Oct 20, 2026, 7:04 PM EDT
Withdrawn No phase listed Observational

Microbiota of the Respiratory Flora in Children With Cystic Fibrosis During the First Year of Life

NCT00977158
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Throat Swab
Procedure
Lead sponsor
Tufts Medical Center
Other
Eligibility
1 Day to 3 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 20, 2026, 7:04 PM EDT
Completed No phase listed Observational

An Evaluation of a Antimicrobial Stewardship Recommendation Bundle for Staphylococcus Aureus Bloodstream Infections

NCT06211829
View directory record Official record
Conditions
Bacterial Infections
Interventions
Not listed
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 85 Years
Enrollment
77 participants
Timeline
2022 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 20, 2026, 7:04 PM EDT
Completed Phase 2 Interventional Results available

Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)

NCT01594827
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Inhaled Vancomycin, Placebo (Sterile Water), Rifampin, Trimethoprim/Sulfamethoxazole (TMP/SMX), Doxycycline, Mupirocin Intranasal Creme, 4% chlorhexidine gluconate liquid skin cleanser
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 20, 2026, 7:04 PM EDT
Terminated Phase 4 Interventional Results available

A Pilot Study of Daptomycin for Antimicrobial Prophylaxis

NCT00572260
View directory record Official record
Conditions
Antimicrobial Prophylaxis
Interventions
daptomycin 6 mg/kg IV
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 20, 2026, 7:04 PM EDT
Terminated No phase listed Observational

Study of the Performance of the KeyPath MRSA/MSSA Blood Culture Test - BTA

NCT01640886
View directory record Official record
Conditions
Bacteremia
Interventions
Not listed
Lead sponsor
MicroPhage, Inc.
Industry
Eligibility
18 Years and older
Enrollment
764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
3
States / cities
Tuscon, Arizona • Los Angeles, California • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Oct 20, 2026, 7:04 PM EDT
Completed Phase 3 Interventional Results available

Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT01984684
View directory record Official record
Conditions
Skin and Subcutaneous Tissue Bacterial Infections, Skin Structures and Soft Tissue Infections
Interventions
delafloxacin, vancomycin, aztreonam
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
31
States / cities
Mobile, Alabama • Montgomery, Alabama • Anaheim, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 20, 2026, 7:04 PM EDT
Completed No phase listed Observational

Network on Antimicrobial Resistance in Staphylococcus Aureus

NCT00341913
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Herndon, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 20, 2026, 7:04 PM EDT
Completed Phase 4 Interventional Results available

Preventing Staphylococcal (Staph) Infection

NCT00108160
View directory record Official record
Conditions
Staphylococcal Infections
Interventions
Mupirocin Ointment [Treatment], Polyethylene Glycol Ointment [Placebo]
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Oct 20, 2026, 7:04 PM EDT
Not listed Phase 4 Interventional

Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence

NCT02566928
View directory record Official record
Conditions
Methicillin-Resistant Staphylococcus Aureus, Recurrence, Staphylococcal Skin Infections, Antibiotic Resistance
Interventions
2% mupirocin ointment, Chlorhexidine wash, Hygiene protocol
Drug · Other · Behavioral
Lead sponsor
Clinical Directors Network
Network
Eligibility
7 Years to 70 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
6
States / cities
Brooklyn, New York • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 20, 2026, 7:04 PM EDT
Completed Phase 3 Interventional Results available

Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia

NCT03138733
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia
Interventions
Ceftobiprole medocaril, Daptomycin
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Chula Vista, California • West Palm Beach, Florida • Butte, Montana + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 20, 2026, 7:04 PM EDT
Terminated Not applicable Interventional Results available

Use of a Loading Dose of Vancomycin in Pediatric Dosing

NCT01290237
View directory record Official record
Conditions
Infection
Interventions
vancomycin hydrocloride
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 18 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 20, 2026, 7:04 PM EDT
Completed Not applicable Interventional

Trial of MRSA Polymerase Chain Reaction for Pneumonia

NCT02660554
View directory record Official record
Conditions
Pneumonia, Methicillin-Resistant Staphylococcus Aureus
Interventions
Polymerase Chain Reaction (PCR)
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 100 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 20, 2026, 7:04 PM EDT
Recruiting Phase 4 Interventional

Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections

NCT06982105
View directory record Official record
Conditions
Methicillin Resistant Staphylococcus Aureus, Osteomyelitis Acute, Septic Arthritis, Orbital Cellulitis, Facial Cellulitis, Mastoiditis, Cervical Adenitis, Retropharyngeal Abscess, Peritonsillar Abscess
Interventions
Trimethoprim Sulfamethoxazole
Drug
Lead sponsor
Indiana University
Other
Eligibility
2 Months to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 20, 2026, 7:04 PM EDT